Free Trial
NASDAQ:JAZZ

Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

Jazz Pharmaceuticals logo
$131.72 +2.06 (+1.59%)
Closing price 04:00 PM Eastern
Extended Trading
$131.71 -0.01 (-0.01%)
As of 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Key Stats

Today's Range
$129.02
$132.53
50-Day Range
$105.93
$131.72
52-Week Range
$95.49
$148.06
Volume
654,862 shs
Average Volume
874,642 shs
Market Capitalization
$7.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$178.67
Consensus Rating
Moderate Buy

Company Overview

Jazz Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
94th Percentile Overall Score

JAZZ MarketRank™: 

Jazz Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 82nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Jazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Jazz Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Jazz Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Jazz Pharmaceuticals are expected to grow by 10.32% in the coming year, from $16.96 to $18.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Jazz Pharmaceuticals is -19.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Jazz Pharmaceuticals is -19.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    Jazz Pharmaceuticals has a PEG Ratio of 8.04. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Jazz Pharmaceuticals has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Jazz Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.74% of the float of Jazz Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Jazz Pharmaceuticals has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Jazz Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Jazz Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.74% of the float of Jazz Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Jazz Pharmaceuticals has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Jazz Pharmaceuticals has recently increased by 2.55%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Jazz Pharmaceuticals has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 32 news articles for Jazz Pharmaceuticals this week, compared to 15 articles on an average week.
  • Search Interest

    20 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 186% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107,630.00 in company stock.

  • Percentage Held by Insiders

    Only 4.30% of the stock of Jazz Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Jazz Pharmaceuticals' insider trading history.
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JAZZ Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the most famous companies in the world by 2030.tc pixel
See More Headlines

JAZZ Stock Analysis - Frequently Asked Questions

Jazz Pharmaceuticals' stock was trading at $123.15 on January 1st, 2025. Since then, JAZZ stock has increased by 7.0% and is now trading at $131.72.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday, August, 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by $2.64. Jazz Pharmaceuticals's revenue was up 2.1% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion.

Top institutional investors of Jazz Pharmaceuticals include LSV Asset Management (4.22%), State Street Corp (3.19%), Ameriprise Financial Inc. (3.08%) and JPMorgan Chase & Co. (2.84%). Insiders that own company stock include Bruce C Cozadd, Seamus Mulligan, Robert Iannone, Renee D Gala, Neena M Patil, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Mary Elizabeth Henderson, Samantha Pearce, Rick E Winningham, Patricia Carr, Mark Douglas Smith and Jennifer E Cook.
View institutional ownership trends
.

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/05/2025
Today
9/03/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:JAZZ
CIK
1232524
Employees
2,800
Year Founded
2003

Price Target and Rating

High Price Target
$217.00
Low Price Target
$147.00
Potential Upside/Downside
+35.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
7.77
P/E Growth
8.04
Net Income
$560.12 million
Net Margins
-9.91%
Pretax Margin
-12.51%
Return on Equity
5.02%
Return on Assets
1.73%

Debt

Debt-to-Equity Ratio
1.17
Current Ratio
1.62
Quick Ratio
1.37

Sales & Book Value

Annual Sales
$4.07 billion
Price / Sales
1.96
Cash Flow
$31.29 per share
Price / Cash Flow
4.21
Book Value
$61.10 per share
Price / Book
2.16

Miscellaneous

Outstanding Shares
60,660,000
Free Float
58,051,000
Market Cap
$7.99 billion
Optionable
Optionable
Beta
0.24

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:JAZZ) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners